Sugi Predict

Sugi Predict / Compounds / SCHEMBL1144665

SCHEMBL1144665

SCHEMBL1144665

OC[C@H]1O[C@@H](n2c(Br)nc3c(O)ncnc32)C(O)C1O

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NADK O95544 2/20 0.60
▸ HSPA5 P11021 2/20 0.59
▸ HSPA8 P11142 2/20 0.59
▸ RXFP1 Q9HBX9 1/20 0.54
▸ GAPDH P04406 2/20 0.52
▸ HSD17B10 Q99714 1/20 0.52
▸ LMNA P02545 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ HBB P68871 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ ADK P55263 3/20 0.50
▸ CDK1 P06493 1/20 0.49
▸ CCNB1 P14635 1/20 0.49
▸ CCNA2 P20248 1/20 0.49
▸ CDK2 P24941 1/20 0.49
▸ CCNA1 P78396 1/20 0.49
▸ SLC29A1 Q99808 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1144664 1.00 NADK (0.60) NADKHSPA5HSPA8RXFP1GAPDH
SCHEMBL8494362 0.88 HSPA5 (0.61) HSPA5HSPA8RXFP1GAPDHHSD17B10
SCHEMBL8494383 0.88 HSPA5 (0.61) HSPA5HSPA8RXFP1GAPDHHSD17B10
SCHEMBL13587343 0.87 NADK (0.79) NADKHSPA5HSPA8RXFP1GAPDH
SCHEMBL1106674 0.87 NADK (0.79) NADKHSPA5HSPA8RXFP1GAPDH
SCHEMBL20419274 0.87 NADK (0.79) NADKHSPA5HSPA8RXFP1GAPDH
SCHEMBL6671819 0.87 NADK (0.79) NADKHSPA5HSPA8RXFP1GAPDH
SCHEMBL440925 0.87 NADK (0.79) NADKHSPA5HSPA8RXFP1GAPDH
SCHEMBL12030991 0.87 NADK (0.79) NADKHSPA5HSPA8RXFP1GAPDH
SCHEMBL440926 0.87 NADK (0.79) NADKHSPA5HSPA8RXFP1GAPDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110718-A1 Anti-HCV nucleoside derivatives DEVOS RENE (GB) 2004-06-10 — — US claimed
WO-2002018404-A9 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C HOFFMANN LA ROCHE (CH) 2003-10-02 — — WO claimed
EP-1315736-A2 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C F. HOFFMANN-LA ROCHE AG (CH) 2003-06-04 — — EP claimed
US-20030008841-A1 Anti-HCV nucleoside derivatives F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) 2003-01-09 — — US claimed
WO-2002018404-A2 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C F. HOFFMANN-LA ROCHE AG (CH) 2002-03-07 — — WO claimed
US-12584126-B2 microRNA inhibitors for use in treating metabolic diseases HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) 2026-03-24 — — US disclosed
EP-3775277-B1 METHOD FOR DIAGNOSING DISEASES USING MULTIPLEX FLUORESCENCE AND SEQUENCING MULTIPLEXDX S R O (SK) 2025-12-03 — — EP disclosed
EP-3850099-B1 MICRORNA INHIBITORS FOR USE IN TREATING METABOLIC DISEASES HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) 2025-09-03 — — EP disclosed
US-12404605-B2 Method for diagnosing diseases using multiplex fluorescence and sequencing MultiplexDX, s.r.o. (SK) 2025-09-02 — — US disclosed
CN-112654705-B MicroRNA inhibitors for use in the treatment of metabolic disorders 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） 2024-07-02 — — CN disclosed
US-20240140983-A1 SINGLE STRANDED DNA ENZYME INHIBITORS MASSEY UNIVERSITY (NZ) 2024-05-02 — — US disclosed
US-20230037279-A9 METHOD FOR DIAGNOSING DISEASES USING MULTIPLEX FLUORESCENCE AND SEQUENCING MultiplexDX, s.r.o. (SK) 2023-02-02 — — US disclosed
WO-2001052860-A2 METHOD AND COMPOSITION FOR MODULATING AN IMMUNE RESPONSE INOTEK CORPORATION (US) 2001-07-26 — — WO disclosed
EP-0586523-A4 DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF UNIV YALE (US) 1995-11-29 — — EP disclosed
EP-0586523-A1 DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF YALE UNIVERSITY (US) 1994-03-16 — — EP disclosed
US-5213972-A Production of thymidine and deoxyuridine, intermediates for AZT CHEMGEN CORPORATION (US) 1993-05-25 — — US disclosed
EP-0504279-A4 FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES — 1993-02-17 — — EP disclosed
WO-1992020816-A1 DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF YALE UNIVERSITY (US) 1992-11-26 — — WO disclosed
EP-0504279-A1 FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES. CHEMGEN CORP (US) 1992-09-23 — — EP disclosed
WO-1991009130-A1 FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES CHEMGEN CORPORATION (US) 1991-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008841-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 NADK 134/4885HSPA5 1928/4885HSPA8 1847/4885
US-20040110718-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 NADK 134/4885HSPA5 1928/4885HSPA8 1847/4885
US-12584126-B2 microRNA inhibitors for use in treating metabolic diseases TRDMT1, NSUN3, RNGTT NADK 1733/4885HSPA5 1589/4885HSPA8 2489/4885
US-20240140983-A1 SINGLE STRANDED DNA ENZYME INHIBITORS APOBEC3A, APOBEC3C, APOBEC3G NADK 1065/4885HSPA5 2996/4885HSPA8 3722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.